Kornimate/medical-research-clean huggingface dataset:
neurofeedback for borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: the goal of this study is to evaluate whether rtfmri-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.

we will assess the treatment effects of real-time fmri neurofeedback in adults with borderline personality disorder. this is an experimental longitudinal design where participants will be followed every two weeks after receiving 2 sessions of neurofeedback from the amygdala . procedures involve a battery of self-report measures, fmri and psychophysiological indices (heart rate, respiration).

Eligibility criteria:
inclusion criteria: * right-handed adults (ages 18 - 55) with a primary diagnosis of borderline personality disorder according to diagnostic criteria in the structured interview for dsm personality disorders * must be able to give written informed consent prior to participation * unmedicated or stable on an ssri antidepressant regime (at least 3 weeks to ensure symptoms are stable) * english speaking exclusion criteria: * have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder * current moderate or severe dsm-v alcohol or substance use disorder, with the exception of nicotine or caffeine. clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention. * have a history of traumatic brain injury * are unable to complete mri scan due to claustrophobia or general mri exclusions (e.g., shrapnel inside body) * are currently pregnant or breast feeding * are unable to complete questionnaires written in english * current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except ssri antidepressants) likely to influence cerebral blood flow. effective medications will not be discontinued for the purposes of the study. inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population * have a dsm-5 diagnosis of psychotic or organic mental disorder * have any eye problems or difficulties in corrected vision. * serious suidicial ideation

Keywords: fmri neurofeedback amygdala
a study of ak104/tislelizumab with chemotherapy as first-line treatment in pd-l1 tps < 1% non-small cell lung cancer

Conditions: Locally Advanced or Metastatic NSCLC

Summary: this is a randomized, double-blind, phase iii clinical study to compare the efficacy and safety of ak104 combined chemotherapy versus tislelizumab combined chemotherapy in first-line treatment of locally advanced or metastatic nsclc with pd-l1 tps \< 1%.


Eligibility criteria:
inclusion criteria: 1. the subjects voluntarily participated in the study with full informed consent and signed written informed consent form. 2. aged ≥18 years when the subject signed the informed consent. 3. eastern cooperative oncology group (ecog) performance status of 0 or 1. 4. life expectancy ≥ 3 months. 5. histologically or cytologically confirmed locally advanced (stage iiib/iiic) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (stage iv) nsclc (american joint committee on cancer \[ajcc\] 8th edition). 6. no prior systemic therapy for advanced or metastatic nsclc was received. 7. pd-l1 tps \< 1%. 8. no egfr sensitive mutations or alk gene translocation alterations. exclusion criteria: 1. histologically confirmed small cell lung cancer (sclc). 2. nsclc with driver gene mutations for approved targeted drug indications. 3. active central nervous system (cns) metastases were present. 4. pulmonary radiation therapy \> 30 gy within 6 months prior to first dose. 5. active malignant tumors within the past 5 years, except for tumors in this study and scured local tumors. 6. pregnant or lactating women. 7. clinically significant cardiovascular or cerebrovascular disease. 8. subjects with a known history of severe hypersensitivity to other monoclonal antibodies. a known history of allergy or hypersensitivity to all investigational drugs or any of their components. 9. active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, or autoimmune diseases that may relapse or require scheduled treatment as judged by the investigator. 10. known active pulmonary tuberculosis. 11. patients with active hepatitis b or active hepatitis c. 12. known medical history of immunodeficiency or positive hiv test.
phase 1/2 study of hqk-1001 in patients with beta thalassemia

Conditions: Beta Thalassemia

Summary: the purpose of this study is to evaluate the safety and tolerability of hqk-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia


Eligibility criteria:
inclusion criteria: * clinical diagnosis of beta thalassemia intermedia or hemoglobin e beta thalassemia * average of the initial two hemoglobin levels of less than 10 g/dl within ≥ 30 days prior to randomization. * age ≥ 12 and ≤ 60 years * able and willing to give informed consent or assent (if less than 18 years of age) and comply with all study procedures * if female and of childbearing potential, must have a documented negative pregnancy test at day -1 and must agree to use one or more locally medically accepted methods of contraception in the month prior to randomization, through the entire study, and for 4 weeks after the last dosing of study medication exclusion criteria: * spleen palpable ≥ 2 cm below the left costal margin * pulmonary hypertension requiring oxygen therapy * qtc \> 450 msec on screening ecg * infection with hepatitis c, hepatitis b requiring therapy * known infection with hiv * red blood cell (rbc) transfusions within 2 months prior to administration of study medication with stable hemoglobin levels * fever greater than 38.5°c in the week prior to administration of study medication * alt \> 4x upper limit of normal (uln) * baseline elevation of cpk value prior to randomization * treatment with hydroxyurea within 2 months prior to administration of study medication * cancer diagnosis within 5 years of randomization (except for non-melanoma cutaneous malignancies) * serum creatinine \> 1.5 mg/dl * received investigational systemic therapy within 30 days prior to randomization * currently pregnant or breast feeding a child * subject history of clinically significant arrhythmias or syncope * known current drug or alcohol abuse
assess the ability of metrogel 1% to deliver moisture to facial skin after a single application

Conditions: Rosacea

Summary: this eight-hour kinetic regression clinical study was conducted to assess the ability of metrogel® 1% to deliver moisture to facial skin after a single application.

this eight-hour kinetic regression clinical study was conducted to assess the ability of metrogel® 1% to deliver moisture to facial skin after a single application as measured by the corneometer cm 825.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions exclusion criteria: * individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis
trial comparing intensity modulated radiotherapy versus conformal radiotherapy to treat prostate cancer with hypofractionated schedule

Conditions: Prostate Cancer

Summary: there is no randomized controlled trial (rct) comparing conformal radiotherapy (3dcrt) versus the intensity modulated radiotherapy (imrt) in terms of toxicity and disease control. data from retrospective studies show that imrt reduces the risk of severe late complications. more recently, the results from the rtog 0126 study have also confirmed the benefit from imrt in reducing acute toxicity for prostate cancer treated with conventional dose escalation. therefore, to investigate the real clinical benefit of the imrt over 3dcrt using a hypofractionated schedule in prostate cancer, the investigators developed a rct.


Eligibility criteria:
inclusion criteria: * patients with diagnosis of prostate cancer * with age between 18-75 years classified in low * intermediate and high-risk group according to their gleason score * t stage and initial psa (ipsa). * low risk group included patients with gleason score \<7 / stage t1-t2a, and ipsa \<10 ng/ml. * intermediate risk included gleason score \< 7, or stage t1-t2b, or ipsa level of 10-20 ng/ml * high-risk patients with gleason score \>7, or stage \> t2b, or ipsa \>20 ng/ml. * all patients classified as high risk was submitted to the bone scans. exclusion criteria: * patients with metastases * prior history of prostatectomy * pelvic radiotherapy treatment * chemotherapy treatment were excluded of this trial.

Keywords: hypofractionated schedule intensity modulated radiotherapy conformal radiotherapy
reliability and validation of 3-d electromagnetic tracking during pelvic floor muscle (pfm) activation - a pilot study

Conditions: Pelvic Floor Dyssynergia

Summary: now a days the ultrasound is seen as a valid and reliable measurement tool to test the pelvic floor muscle (pfm) movement (sherburn, murphy, carroll, allen, \& galea, 2005). the hypothesis is that the electromagnetic tracking system, trakstartm, can measure the pfm movement in an equal or even more precise way. the trakstartm will have the advantage to be used in measuring functional movements. in this master thesis the hypothesis is to show a good reliability by trampoline jumping (physical activity).

there will be two measurements. one measurement of mvic and quick flicks will be done in a standing and supine position with 3 repetitions. the trakstartm, ultrasound, surface emg and accelerometer will measure the pfm movements and activation simultaneously. the ultrasound is measured from one tester (to guaranty a high intratester reliability) (sherburn et al., 2005). trakstartm, surface emg and accelerometer will measure 3 trampoline jumps. the measurements will be done once during one hour. the women will insert the vaginal probe by themselves and stay dressed during the measurement procedure. the measurements will be done in a standardized way. all the arrangements are made to ensure the hygiene requirements.

Eligibility criteria:
inclusion criteria: * women * aged between 18 and 35 years * anamnestically healthy * nulliparous and * a bmi between 18 and 30 exclusion criteria: * latex and nickel allergy * anamnestically current pregnancy * menstruation * urogenital operations * anal operations * vaginal infections

Keywords: pelvic floor ultrasonography
evaluating instrumentation for dental devices used in treating sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: oral appliances are an accepted means to treat obstructive sleep apnea. we propose to develop monitoring sensors that could be inserted into commercially available oral appliances in order to monitor effectiveness of the oral appliances in treating sleep apnea.

oral appliances are an accepted means to treat obstructive sleep apnea. in order to determine if they are effective, a polysomnogram needs to be conducted with the oral appliance in place. we propose to develop monitoring sensors that could be inserted into commercially available oral appliances in order to monitor effectiveness of the oral appliances in treating sleep apnea. we propose to look at heart rate variability as a marker for ongoing sleep apnea. we will use temperature as means of detecting how long the device is in the mouth as a means of assessing adherence. the objective of the phase i project is to validate this hypothesis by answering five questions: * what is the optimal sensor suite? we will determine the optimal suite of sensors that provides adequate sensitivity and specificity to determine oa usage and effectiveness without compromising patient comfort. * can we develop designs that are compatible with the most popular oas? we will design and develop prototype versions of the oams that are compatible with three of the most popular commercially available oams products (potential candidates include ema, tap, somnodent, herbst, suad). * do experienced dental care providers who specialize in oas approve of the designs? we will collaborate with dental care clinicians to iteratively refine the oams design for maximum performance and patient comfort. * does the oams provide data that are consistent with psg instrumentation? we will collaborate with the dartmouth-hitchcock medical center (dhmc) sleep disorders laboratory to assess oams sensor accuracy for approximately five healthy volunteers by comparing osa-related oams data with data from standard psg instrumentation. * can we formulate a cogent human subject testing plan for phase ii? we will develop a detailed hst study plan to be conducted in phase ii to demonstrate fully integrated and functional oams in a broad range of osa patients who are candidates for an oa.

Eligibility criteria:
inclusion criteria: * ages 21-65 * diagnosed with obstructive sleep apnea actively treated with an oral appliance or interested in transitioning to an oral appliance * ability to give informed consent exclusion criteria: * significant physical illness that might impair the ability to participate * pregnant women will be excluded * subjects presently taking medication such as beta blockers or alpha agonists know to alter the autonomic nervous system

Keywords: oral appliance
effect of light emitting diode therapy on muscle fatigue

Conditions: Muscle Fatigue

Summary: the purpose of this study is to determine the optimal time interval between light emitting diode application and exercise to improve fatigue resistance.the results of this study could be useful in planning a rehabilitation program in musculature disorders and also in athletic training.

1. to determine the effect of light emitting diode applied 5 minutes before exercise on pain, rate of perceived exertion and maximum voluntary contraction. 2. to determine the effect of light emitting diode applied 1 hour before exercise on pain, rate of perceived exertion and maximum voluntary contraction. 3. to determine the effect of light emitting diode applied 5 hours before exercise on pain, rate of perceived exertion and maximum voluntary contraction. 4. to determine the difference between light emitting diode applied 5 minutes,1 hour or 5 hours before exercise on pain, rate of perceived exertion and maximum voluntary contraction.

Eligibility criteria:
inclusion criteria: * healthy non athletics subjects. * age ranges from 20-40 years. * body mass index is less than 25 kg/m 2 exclusion criteria: * neurological deficit and recent injury to either upper extremity * non diagnosed pain . * contraindications to led irradiation (such as light hypersensitivity, fluctuating blood pressure, insufficient blood circulation, fever and inflammation of the skin) * conditions in which physical exertion is contraindicated (such as cardiovascular deficits, hypertension and respiratory problems) * restriction in shoulder or elbow range of motion; * neoplasm, * rheumatoid, * strength training in the past 6 months; * previous surgery in the spine or upper extremity; * complaints of pain in the shoulder, elbow,wrist, and trunk musculature system; * use of dietary supplements; and not in any other exercise program for at least the past 3 months.
safety study of thermal stimulation on upper extremity motor recovery to stroke

Conditions: Stroke

Summary: improving upper extremity movement and function in patients with stroke has been one of the primary goals for patients and rehabilitation professionals. thermal stimulation (ts) had been first found by a domestic research group to be effective to facilitate sensory and motor recovery in patients with stroke within a month. however, the immediate and long-term effects of ts and the mechanism of brain plasticity in patients with stroke for more than three months (golden recovery stage) remain unknown. thus, we will design a single-blind randomized controlled trial to investigate the immediate and long-term effects of ts in patients with stroke at subacute and chronic stages.

the study was an assessor-blinded randomized controlled clinical trial. participants with ue impairment for more than 3 months poststroke were randomly assigned to either the experimental (exp) group or the control group. all participants received regular conventional rehabilitation programs. the exp group received an additional ue-ts protocol for 30 minutes a day (3 days/week for 8 weeks); the control group received the same ts protocol over the lower extremity (le). the brunnstrom's recovery stage, the modified ashworth scale (mas), the stroke rehabilitation assessment of movement (stream), the action research arm test (arat), and the barthel index (bi) were outcome measures and were administered at baseline, 4 weeks and 8 weeks post inception, and at one-month follow-up.

Eligibility criteria:
inclusion criteria: 1. first-ever stroke survivors with unilateral hemispheric lesions from a hemorrhagic or nonhemorrhagic stroke; 2. stroke onset more than 3 months and less than 3 years prior to study enrollment; 3. no severe cognitive impairments and able to follow instructions; 4. the ability to sit on a chair for more than 30 minutes independently. exclusion criteria: 1. musculoskeletal or cardiac disorders that could potentially interfere with experimental tests; 2. diabetic history or sensory impairment attributable to peripheral vascular disease or neuropathy; 3. speech disorder or global aphasia; 4. participating in any experimental rehabilitation or drug studies; 5. skin injuries, burns, or fresh scars at the sites of stimulation; 6. contraindication of heat or ice application.

Keywords: thermal stimulation upper extremity motor recovery stroke
patient-centered care transitions in heart failure: a pragmatic cluster randomized trial

Conditions: Heart Failure

Summary: heart failure (hf) is the most common cause of hospitalization in older adults. the month after hospital discharge represents a vulnerable period, when patients are at increased risk of death and readmission to hospital. research has shown that certain discharge-planning services can reduce death and readmissions, but these have not been widely implemented. in this study, we will group evidence-informed discharge-planning services into 'patient-centered care transitions in hf' (pact-hf), a model of care that will prepare patients for their transition from hospital to home. through pact-hf, patients will benefit from a comprehensive assessment of their health care needs, learn to recognize and manage symptoms of hf, and receive the information and follow-up care needed to optimize their health. we will introduce pact-hf to 10 ontario hospitals over a number of time periods using a stepped wedge cluster trial design. we will compare the outcomes (hierarchically ordered) of patients in hospitals with pact-hf to those in hospitals without pact-hf. we anticipate that patients hospitalized at the sites with pact-hf will have fewer readmissions, emergency visits, and deaths after discharge; report a better quality of life; and feel more prepared for discharge. we also anticipate that overall, pact-hf will reduce health system costs.


Eligibility criteria:
inclusion criteria: * in participating hospitals, all patients hospitalized with the most responsible diagnosis of heart failure exclusion criteria: * patients who die during hospitalization or are transferred to another hospital

Keywords: heart failure transitional care knowledge translation outcomes
cognitive functions and bdnf in t2dm and prediabetes patients

Conditions: Diabetes Type 2; PreDiabetes; Cognitive Impairment

Summary: clinical and epidemiological studies suggest links between cognitive impairments and type 2 diabetes (t2dm). the underlying mechanisms and causality in diabetes-related cognitive impairment are largely unknown. the aim of this study is to investigate cognitive impairment and the role of bdnf in prediabetes and diabetes patients.

cognitive dysfunction is increasingly recognized as a common complication and comorbidity in both type 1 and type 2 diabetes (t2dm). due to the increasing incidence of diabetes and the life expectancy of individuals with t2dm, it is important to determine the cognitive problems and related factors in these patients. cognitive impairment can be observed in all age groups in individuals with diabetes, and its severity can range from mild cognitive impairment to dementia. although there are few studies in the literature investigating cognitive impairment in prediabetes, it is not clear whether it is a risk factor. the number of studies investigating biomarkers of potential importance for understanding changes in the brain of t2dm patients is increasing rapidly. the relationship of biomarkers associated with the main pathologies of dementia, including alzheimer's disease (ad) and vascular disease, as well as various biomarkers associated with brain parenchymal damage, blood flow and metabolism, with the cognitive status of diabetic patients are investigated. it has been determined in animal experiments that brain induced neurotrophic factor (bdnf) may be among the molecular factors linking t2dm with dementia neuropathology. it has also been stated that high glucose levels are associated with cognitive impairment and total hippocampal volume reductions, and hippocampal changes can be used as an early marker of diabetes-related brain damage. considering that the expression of bdnf in the brain is high in hippocampus neurons, it may be an early marker of cognitive impairment in diabetes. this research is a cross-sectional observational study. the aim of this study is to investigate cognitive impairment and the role of bdnf in prediabetes and diabetes patients.

Eligibility criteria:
inclusion criteria: * age from 30 to 65 years * having at least primary school education exclusion criteria: * severe psychiatric (e.g,major depressive disorder) or neurologic disorder (demyelinating diseases, stroke or brain tumor) * using insulin (insulin therapy was taken as an exclusion criterion to avoid the effect of hypoglycemia on cognition) * vision and hearing problem * hypothyroidism, b12 and folic acid deficiency * advanced chronic renal failure (stage 4-5) * uncontrolled hypertension * patients with hypoglycemia-hyperglycemia attacks * alcohol, substance addiction.

Keywords: diabetes bdnf t2dm prediabetes cognition
comparison of skin prick testing results of local and imported pollen allergen extracts and specific ige

Conditions: Immediate Type Hypersensitivity

Summary: pollen allergen extracts are prepared locally and checked for efficacy by comparison to imported allergens and specific ige.

skin prick test (spt) and specific ige (sige) are approved for evaluation of allergen sensitization. local allergen extracts are cheaper and more available but need standardization. pollen allergen extracts: bermuda, johnson and careless weed are locally prepared and compared mean wheal diameter of skin prick test to imported allergens and also to specific ige.

Eligibility criteria:
inclusion criteria: * positive skin prick test to bermuda or johnson or careless weed exclusion criteria: * chronic diseases such as heart disease, liver, renal and severe sepsis * severe allergic symptoms such as anaphylaxis * extensive skin rashes * pregnancy

Keywords: skin prick test grass and weed pollens